2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Relapsed Classic Hodgkin Lymphoma: new trials by email Literature Review of Relapsed Classic Hodgkin Lymphoma trials Research Report on Relapsed Classic Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma Azacitidine Plus PD-1 therapy - Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 | Recruiting | Navy General Hospital, Beijing | 40 | 2023-10-30 | 2024-01-30 |
| Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Brentuximab Vedotin, Nivolumab - Relapsed Classic Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 31 | 2021-11-12 | 2026-09-22 |
Azacitidine (1) · Brentuximab Vedotin (1) · Nivolumab (1)
City of Hope Medical Center (1) · Navy General Hospital, Beijing (1)
China (1) · United States (1)
Alex F Herrera (1) · Liren Qian, PhD (1)
P30CA033572 (1)